Part 6/9:
Shifting focus, the podcast also explored Biogen's recent $1 billion deal with Ionis Pharmaceuticals. This agreement, announced on April 20, includes a sizeable upfront payment of $375 million and equity stakes amounting to approximately $625 million. Biogen's investment is primarily aimed at acquiring clinical-stage candidates in Ionis’s pipeline, particularly anti-sense drugs targeting neurological diseases.